Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
colorectal cancer
Biotech
High dose of Cardiff's KRAS drug shows 64% ORR, sending stock up
Cardiff reported deeper tumor responses among the patients receiving the 30-mg dose of the biotech's drug compared to those receiving 20 mg.
Gabrielle Masson
Dec 10, 2024 4:05pm
Guardant awarded $292M in false advertising suit against Natera
Nov 26, 2024 10:45am
Engineered yeast delivers PD-1 inhibitors, shrinks mice tumors
Nov 22, 2024 3:12pm
FDA approves Exact Sciences’ next-gen Cologuard Plus home test
Oct 4, 2024 12:30pm
Cash-strapped Gritstone starts search for strategic alternatives
Oct 1, 2024 10:07am
Merck's LAG-3 combo fails colorectal cancer phase 3 study
Sep 25, 2024 8:35am
